布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病的临床疗效及其对患者肺功能的影响
|
摘要
目的探讨布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病的临床疗效及其对患者肺功能的影响。方法选取上海市黄浦区肿瘤防治院2015年8月—2016年12月收治的慢性阻塞性肺疾病患者94例,按照随机数字表法分为对照组和观察组,各47例。对照组患者采用特布他林治疗,观察组患者在对照组基础上联合布地奈德雾化吸入治疗,两组患者均持续治疗2个疗程。比较两组患者治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV_1/FVC、最大呼气流速(PEF)]及血气分析指标[动脉血二氧化碳分压(PaCO_2)、动脉血氧分压(PaO_2)],并观察两组患者不良反应发生情况。结果治疗前,两组患者FVC、FEV_1、FEV_1/FVC、PEF比较,差异无统计学意义(P>0.05);治疗后,观察组患者FVC、FEV_1、FEV_1/FVC、PEF高于对照组(P<0.05)。治疗前,两组患者PaO_2、PaCO_2比较,差异无统计学意义(P>0.05);治疗后,观察组患者PaO_2高于对照组,PaCO_2低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病的临床疗效确切,其可明显改善患者肺功能及血气分析指标,且安全性较高。
Objective To discuss the clinical effect of budesonide combined with terbutaline aerosol inhalation in treating chronic obstructive pulmonary disease and the impact on pulmonary function of patients.Methods A total of 94 cases of chronic obstructive pulmonary disease patients were selected from August 2015 to December 2016 in Shanghai Huangpu District Cancer Hospital,which were divided into control group and observation group,47 cases in each group.The control group was treated with terbutaline,observation group was treated with budesonide,both groups were treated for 2 courses.The pulmonary function indexes(FVC,FEV_1,FEV_1/FVC,PEF)and blood gas analysis indexes(PaO_2,PaCO_2)before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results Before treatment,no significant differences of FVC,FEV_1,FEV_1/FVC or PEF was found between the two groups(P>0.05);after treatment,the observation group of FVC,FEV_1,FEV_1/FVC,PEF were higher than control group(P<0.05).Before treatment,no significant differences of PaO_2 or PaCO_2 was found between the two groups(P>0.05);after treatment,the observation group of PaO_2 was higher than control group,PaCO_2 was lower than control group(P<0.05).There was no significant difference of the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Budesonide combined with terbutaline aerosol inhalation have an exact clinical effect in treating chronic obstructive pulmonary disease,which can effectively improve the pulmonary function and blood gas analysis of patients,and with high safety.
Objective To discuss the clinical effect of budesonide combined with terbutaline aerosol inhalation in treating chronic obstructive pulmonary disease and the impact on pulmonary function of patients.Methods A total of 94 cases of chronic obstructive pulmonary disease patients were selected from August 2015 to December 2016 in Shanghai Huangpu District Cancer Hospital,which were divided into control group and observation group,47 cases in each group.The control group was treated with terbutaline,observation group was treated with budesonide,both groups were treated for 2 courses.The pulmonary function indexes(FVC,FEV_1,FEV_1/FVC,PEF)and blood gas analysis indexes(PaO_2,PaCO_2)before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results Before treatment,no significant differences of FVC,FEV_1,FEV_1/FVC or PEF was found between the two groups(P>0.05);after treatment,the observation group of FVC,FEV_1,FEV_1/FVC,PEF were higher than control group(P<0.05).Before treatment,no significant differences of PaO_2 or PaCO_2 was found between the two groups(P>0.05);after treatment,the observation group of PaO_2 was higher than control group,PaCO_2 was lower than control group(P<0.05).There was no significant difference of the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Budesonide combined with terbutaline aerosol inhalation have an exact clinical effect in treating chronic obstructive pulmonary disease,which can effectively improve the pulmonary function and blood gas analysis of patients,and with high safety.
引文
[1]白蓉,王娟,段宝萍,等.盐酸氨溴索和异丙托溴铵治疗慢性阻塞性肺疾病急性加重期患者的效果观察[J].中国综合临床,2013,29(8):794-796.
[2]黄桔红,姚必瑜.布地奈德联合特布他林雾化治疗在慢性阻塞性肺病中的应用及对炎性因子的影响[J].中国生化药物杂志,2017,37(2):246-248.
[3]谢芳芳,温连英.特布他林联合布地奈德雾化吸入对慢性阻塞性肺疾病急性加重期疗效及护理观察[J].中国药业,2016,25(23):92-94.
[4]魏华.连花清瘟胶囊联合特布他林和布地奈德治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2016,31(7):973-977.
[5]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[6]李晓佳,张俊林,金雪梅,等.糖皮质激素联合特布他林治疗慢性阻塞性肺疾病急性加重期对肺功能及预后的影响[J].中国实用医药,2013,8(9):62-63.
[7]乔曼,李冬生,徐桐柏,等.特布他林联合福多司坦治疗缓解期慢性阻塞性肺疾病的临床研究[J].现代药物与临床,2017,32(5):826-830.
[8]贾长龙,王伟强,李淼,等.特布他林和异丙托溴铵联合糖皮质激素在慢性阻塞性肺疾病急性加重期的应用[J].贵阳医学院学报,2014,39(4):587-588,590.
[9]费建荣,朱佳威.自拟宣肺止咳平喘汤联合布地奈德治疗AECOPD的效果及对炎症因子和肺功能的影响[J].中国生化药物杂志,2017,37(6):147-148.
[10]李新鹏.布地奈德福莫特罗联合呼吸康复训练治疗慢性阻塞性肺疾病的疗效观察[J].中国临床医生杂志,2017,45(5):41-43.
[11]伍进,张连生,钟连江.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性发作61例[J].中国药业,2013,22(9):57-58.
[12]金小薇,吴苏春.布地奈德联合硫酸特布他林雾化吸入治疗慢性阻塞性肺疾病30例[J].中国药业,2013,22(9):110-111.
[13]宋丽杰.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果观察[J].心理医生,2018,24(35):75.
[14]袁晖.硫酸特布他林联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的效果观察[J].山西医药杂志,2018,47(15):1790-1791.DOI:10.3969/j.issn.0253-9926.2018.15.018.
[15]胡建勋.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病患者的疗效[J].医疗装备,2018,31(14):98-99.
[2]黄桔红,姚必瑜.布地奈德联合特布他林雾化治疗在慢性阻塞性肺病中的应用及对炎性因子的影响[J].中国生化药物杂志,2017,37(2):246-248.
[3]谢芳芳,温连英.特布他林联合布地奈德雾化吸入对慢性阻塞性肺疾病急性加重期疗效及护理观察[J].中国药业,2016,25(23):92-94.
[4]魏华.连花清瘟胶囊联合特布他林和布地奈德治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2016,31(7):973-977.
[5]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[6]李晓佳,张俊林,金雪梅,等.糖皮质激素联合特布他林治疗慢性阻塞性肺疾病急性加重期对肺功能及预后的影响[J].中国实用医药,2013,8(9):62-63.
[7]乔曼,李冬生,徐桐柏,等.特布他林联合福多司坦治疗缓解期慢性阻塞性肺疾病的临床研究[J].现代药物与临床,2017,32(5):826-830.
[8]贾长龙,王伟强,李淼,等.特布他林和异丙托溴铵联合糖皮质激素在慢性阻塞性肺疾病急性加重期的应用[J].贵阳医学院学报,2014,39(4):587-588,590.
[9]费建荣,朱佳威.自拟宣肺止咳平喘汤联合布地奈德治疗AECOPD的效果及对炎症因子和肺功能的影响[J].中国生化药物杂志,2017,37(6):147-148.
[10]李新鹏.布地奈德福莫特罗联合呼吸康复训练治疗慢性阻塞性肺疾病的疗效观察[J].中国临床医生杂志,2017,45(5):41-43.
[11]伍进,张连生,钟连江.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性发作61例[J].中国药业,2013,22(9):57-58.
[12]金小薇,吴苏春.布地奈德联合硫酸特布他林雾化吸入治疗慢性阻塞性肺疾病30例[J].中国药业,2013,22(9):110-111.
[13]宋丽杰.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果观察[J].心理医生,2018,24(35):75.
[14]袁晖.硫酸特布他林联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的效果观察[J].山西医药杂志,2018,47(15):1790-1791.DOI:10.3969/j.issn.0253-9926.2018.15.018.
[15]胡建勋.布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病患者的疗效[J].医疗装备,2018,31(14):98-99.